Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …

Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …

Abstract The 2021 WHO Classification of Thoracic Tumours was published earlier this year,
with classification of lung tumors being one of the chapters. The principles remain those of …

Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median
overall survival of only about 13 months, indicating the urgent need for novel therapies …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …